ABSTRACT. Mutations in the CYP1B1 gene were detected in primary openangle glaucoma (POAG) patients. However, the association between these mutations and the incidence of POAG remains to be elucidated. Here, we have conducted a meta-analysis to analyze this correlation, using relevant studies obtained from an extensive search of various electronic databases, including EMBase, Web of Science, and PubMed. The extracted studies were selected for the meta-analysis based on the inclusion and exclusion criteria. The quality of each included study was assessed by the Newcastle- Ottawa scale (NOS), and the I 2 value was calculated to evaluate the heterogeneity between studies. The combined effect size was presented as the odds ratio (OR), and confidence intervals (CI) were used to assess the association between POAG and CYP1B1 mutations. Eight studies, each with a high NOS score, were included in the analysis. Compared to the mutant allele, the wild-type allele of the rs180040 polymorphism in POAG patients showed a 12% decrease in OR (OR = 0.88, 95%CI = 0.76-1.00); also, the wild-type allele of rs1056827 showed a 23% decrease in OR of the incidence of POAG (OR = 0.77, 95%CI = 0.60-0.99). However, the latter result was controversial. Polymorphisms at rs1056836, rs10012, and rs1056837 were not correlated with the incidence of POAG (using any evaluation model). In conclusion, three of the tested SNPs in the CYP1B1 gene were correlated with POAG; however, the SNPs rs180040 and rs1056827 showed an association with risk of POAG. These results must be further validated with larger-scale evaluations.
This meta‐analysis was conducted to estimate the association between matrix metalloproteinase‐1 (MMP‐1) expression and pelvic organ prolapse (POP) in women. Relevant studies published before 6 December 2015 were identified by searching PubMed, Ovid, EBSCO, and EMBASE. A total number of five case–control studies, including 182 POP cases and 192 controls, were identified. The results indicated that women without POP had a lower MMP‐1 level of expression compared with women with POP (odds ratio = 0.54, 95% confidence interval: 0.43–0.67, P = 0.000). After stratification by biopsy site, ethnicity, or menopausal status, this finding was also confirmed in the subgroup analysis with no significant changes. Egger's linear regression test revealed a potential publication bias (P = 0.028). The findings of our study indicate that women who suffer from POP have a higher expression level of MMP‐1 than women without POP.
Many studies have analyzed the association between between GSTT1 polymorphism and esophageal cancer, however, the results remained inconclusive. We therefore performed an updated meta-analysis based on Chinese individuals. PubMed, Springer Link, Ovid, Chinese Wanfang Data Knowledge Service Platform, Chinese National Knowledge Infrastructure and Chinese Biology Medicine were searched up to December 2016. An OR with the corresponding 95% CI was used to assess the strength of the association. This meta-analysis included 12 studieswith 1246 cases and 1863 controls. Overall, GSTT1 null genotype was associated with an increased esophageal cancer risk when all studies in Chinese populations pooled into this meta-analysis. In stratified studies with geographical location, significantly increased risk was found in North China (OR = 1.45, 95%CI: 1.11-1.91) and in studies with population-based control (OR = 1.29, 95%CI: 1.07-1.55). This study suggested that GSTT1 null genotype may be potential biomarkers for esophageal cancer in China, especially in North China. Studies with larger sample sizes and wider spectrum of populations are warranted to verify this finding.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.